trial summary · NCT07389980
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Polypoidal Choroidal Vasculopathy, sponsored by Yeungnam University College of Medicine. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
Source record: https://clinicaltrials.gov/study/NCT07389980
Facts
| registry id | NCT07389980 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Polypoidal Choroidal Vasculopathy |
| sponsor | Yeungnam University College of Medicine |
| sponsor class | OTHER |
| enrollment | 50 |
| start date | 2026-12-24 |
| primary completion | 2028-11 |
| completion | 2028-12 |
| results posted | not reported |
Conditions
- Polypoidal Choroidal Vasculopathy
- Polypoidal Choroidal Vasculopathy (PCV)
Interventions
- aflibercept 8 mg
Countries
- South Korea
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.